Connect with us

BUSINESS

Health Canada Grants License Amendment To PharmHouse Inc, A JV Of Canopy Rivers Inc (OTCMKTS:CNPOF), To Commence Cultivation In Its Greenhouse

Published

on

Health Canada has granted a license amendment to PharmHouse Inc, a JV of Canopy Rivers Inc (OTCMKTS:CNPOF), to begin cultivation in its operational Greenhouse. PharmHouse expects to increase production immediately to meet the offtake agreements with TerrAscend Canada Inc and Canopy Growth Corporation. The JV earmarks 50% of its output in 2020 to these accords. It will use balance 50% of the output for its private label brand and additional offtake accords.

License amendment is a great milestone

General Manager of PharmHouse, Tony Abbas, said the license amendment from Health Canada represents a great achievement for the company. He said it is a result of the dedication and hard work put in by the team in 2019. The team at PharmHouse has put in great efforts since its establishment to achieve the goal of bringing innovation and consistency in cannabis cultivation at the Greenhouse. It expects to change the concept of commercial cannabis manufacturing using the market presence and experience of the partners and with its full production capacity.

Canopy Rivers owns a 49% stake in PharmHouse

Canopy Rivers holds a stake of 49% in PharmHouse. Mastronardi Produce Limited will contribute its expertise in the distribution, production, and marketing of agriculture products to the JV. Canopy Rivers and Mastronardi have coordinated to develop an EU-GMP compliant automated facility. They will leverage their strengths in marketing, commercial agriculture, and cannabis.

Chief Executive Officer and President of Canopy Rivers, Narbe Alexandrian, congratulated the entire team at PharmHouse for this great milestone. The technology-driven achievement of PharmHouse to cannabis cultivation and its capability to use the expertise of the JV partners helps to meet its goals.

TerrAscend Canada Inc enters a finance arrangement

TerrAscend Canada Inc, a wholly-owned subsidiary of TerrAscend, entered a loan finance arrangement for CAD 80.5 million with Canopy Growth Corporation. As per the terms of the agreement, Canopy Growth has received 17.808 million purchase warrants from TerrAscend. Narbe said it shows confidence in the capability of TerrAscend Canada to execute its strategic mandate for international and domestic markets. He further said the team at TerrAscend is well-positioned to benefit from the opportunities in the regulated jurisdictions using its network and resources.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Can B Corp (OTCMKTS: CANB) Signs Partnership To Market CBD Products and Releases Q1 2021 Results

Published

on

Can B Corp (OTCMKTS: CANB) has entered a partnership with a company comprising World Champion Action Sports Athletes and Professional Hollywood Stuntmen to market the Can B Corp’s existing select CBD products and launch a new CBD brand at the end of the summer. 

Can B enters a partnership for its CBD products 

Notably, the Professional Hollywood Stuntmen group lists film credits include The Hunger Games, Breaking bad, Ant-Man, Twilight Saga, Fast & Furious 7, Jason Bourne, Mulan, The Expendables Better Call Saul, and others. Additionally, the group will commence marketing Can B Corp’s CBD products Slave 100& 200 mg and CryoGel Gold 500 mg. 

Can B CEO Marco Alfonsi said, “This is a really exciting new partnership for our Company, as it provides a new untapped distribution channel for our manufacturing and production, which remains under-utilized. Our Lacey, Washington facility continues to have an excess capacity which we can use for new private label customers. This group of Professional Hollywood Stuntmen and World Champion Action Sports Athletes has great exposure and a wide social media following, which they will utilize to market and advertise the CBD products.”

Can B’s Q1 2021 revenue dropped 46%

Recently the company announced its Q1 2021, during which revenue was $306,940, a 46% YoY decline. The drop resulted from the pandemic’s impact leading to the halting of elective surgeries, which is the primary medical device revenue source for the company. Additionally, some distributors lost clients because of business closure impacting the company’s overall revenue. During the quarter, the company closed the acquisition of talent and assets from Botanical Biotech. 

Alfonsi stated, “While we experienced a decline in our revenue due to Covid-19’s negative impact on markets we serve in elective surgeries and lost clients due to business closings of certain distributors, we have taken the time to maintain and strengthen our vertically integrated platform.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

The Valens Company Inc. (OTCMKTS: VLNCF) Signs Production and Distribution Deal with Harvest One

Published

on

The Valens Company Inc. (OTCMKTS: VLNCF) has entered a two-year deal with Harvest One Cannabis Inc. as a provincial partner and white label manufacturer for cannabis-infused tropicals for LivReleif, its leading brand. 

Harvest One launched LivRelief in 2020

Harvest One is a global marijuana infusion CPG operator that distributes high-quality self-care and wellness products, and it launched its leading cannabis-infused LivRelife products portfolio last year. Notably, since last year the products line has grown to be the number one cannabis-infused topicals selling brand in Ontario. 

LivRelief is created through natural ingredients for deep penetration utilizing a novel transdermal delivery system that allows CBD to reach target areas. It is a growing cannabis-infused topical creams line that is available in their formats, including 1:1 formulation with 125mg THC and CBD, CBD only formulation with 250mg of CBD, and the recently launched extra strength CBD cream containing 750mg CBD. Currently, the products are available nationally through Medical Cannabis by Shoppers and at various private and provincial retailers. 

Harvest One and Valens to expand distribution of LiRRelief

Through the partnership, The Valens and Harvest One will expand distribution and enhance customer awareness and brand loyalty nationwide. The first product shipments from Valens’ facilities will begin in fiscal Q4 2021. 

Valens CEO Tyler Robson said, “The LivRelief cannabis-infused topical brand has established itself as a premium and reliable provider of cannabis-infused topicals with a leading-edge proprietary transdermal delivery system that took years of research, innovation, and dedication to develop. We are proud to manufacture these top-selling creams in partnership with Harvest One and provide both new and experienced consumers the comfort to engage with cannabis-infused topicals. Valens already manufactures the number one selling bath product in Ontario3 and now adds the number one selling cannabis-infused topical brand to its portfolio, making it a clear leader in both the topicals and health and wellness verticals in Canada.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Vivo Cannabis Inc. (OTCMKTS: VVCIF) Receives Permit to Import Dried Medical Cannabis to Germany

Published

on

Vivo Cannabis Inc. (OTCMKTS: VVCIF) has announced that it’s EU-GMP/GDP licensed affiliate Beacon Medical Germany GmbH has been granted an import permit by Germany’s Federal Institute for Drugs and Medical Devices.  With the grant to the permit, the company can now import Canadian grown dried medical cannabis flower from Vivo’s ABcann Medicinal subsidiary’s GMP-certified Napanee, Ontario site into the EU. 

Vivo taking steps to commercialize the product in Europe

Vivo holds cannabis licenses under the Cannabis ACT through its subsidiaries ABcann Medicinals Inc. and Canna Farms Limited. 

Canna Farms Co-founder and VIVO CEO Ray Laflamme said, “We are making great strides towards our first commercialization of product in Europe. As a leader in medical cannabis in Canada and Australia, we are delighted by the opportunity to bring our Beacon Medical™ products to market and support the increasing demand from Germany’s more than 130,000 medical cannabis clients.”

The import permit received is issued on a shipment-by shipment basis. After receiving the export approval from Health Canada, the company will ship its first product in late Q3 or ear Q4, which will be offered under the Beacon medical brand. 

Vivo Cannabis launched Canna Farms Brick Hash

The company recently launched Canna Farms Brick Hash, a high-quality, solventless, all-natural concentrate consumed as an edible through inhalation. Hashish is produced through resin extraction from cannabis and converting it into a solid form. Canna Farms Brick Hash is produced using modern tech and solvent-free extraction at the Hope facility. The novel process starts with blended Kief input from premium dried marijuana. Next, the hashish is slow-cooked and pressed, under pressure, cured, and wrapped in parchment to perfection for 30 days.

Laflamme said, “Our team has worked hard to perfect our process, and we’re very proud to bring to market another premium craft medical product catered to clients needing higher potency dosing.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories